Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs Indian Medical PG Practice Questions and MCQs

Question 191: Drug H is most like which of the following agents?

A. Epinephrine (Correct Answer)
B. Isoproterenol
C. Norepinephrine
D. Phenylephrine

Explanation: ***Epinephrine*** - Drug H demonstrates activity at **all adrenergic receptor subtypes** (α1, α2, β1, β2), which perfectly matches **epinephrine's broad receptor profile**. - Epinephrine is a **non-selective adrenergic agonist** that activates both **alpha and beta receptors** with equal potency, producing diverse physiological effects. *Isoproterenol* - Acts as a **selective β-adrenergic agonist** (β1 and β2) with **no alpha receptor activity**. - Would not match Drug H's profile since it lacks **α1 and α2 receptor stimulation**. *Norepinephrine* - Primarily activates **α1, α2, and β1 receptors** but has **minimal β2 activity**. - Differs from Drug H because it shows **weak or absent β2 receptor stimulation**. *Phenylephrine* - Functions as a **selective α1-adrenergic agonist** with **no beta receptor activity**. - Cannot match Drug H's profile due to complete absence of **β1 and β2 receptor stimulation**.

Question 192: Which of the following drugs is used as a diagnostic tool?

A. Cevimeline
B. Vedolizumab
C. Tensilon (Correct Answer)
D. Sacubitril

Explanation: **Explanation:** **Tensilon (Edrophonium)** is the correct answer because it is a classic diagnostic tool used in the **Tensilon Test** for **Myasthenia Gravis (MG)**. Edrophonium is a very short-acting reversible acetylcholinesterase inhibitor. By inhibiting the breakdown of acetylcholine at the neuromuscular junction, it temporarily increases the concentration of the neurotransmitter. In patients with MG, this leads to a rapid, transient improvement in muscle strength (especially ptosis), confirming the diagnosis. **Analysis of Incorrect Options:** * **Cevimeline (A):** This is a synthetic muscarinic agonist (M1 and M3 selective) used primarily for the **treatment** of xerostomia (dry mouth) in Sjögren’s syndrome, not for diagnosis. * **Vedolizumab (B):** This is a monoclonal antibody that binds to α4β7 integrin. It is used as a **therapeutic** agent in the management of inflammatory bowel diseases like Crohn’s disease and Ulcerative Colitis. * **Sacubitril (D):** This is a neprilysin inhibitor used in **combination with Valsartan (ARNI)** for the treatment of chronic heart failure with reduced ejection fraction. **High-Yield Clinical Pearls for NEET-PG:** * **Tensilon Test:** Due to the risk of bradycardia or bronchospasm during the test, **Atropine** should always be kept ready as an antidote. * **Differentiation:** Edrophonium is also used to differentiate between a **Myasthenic Crisis** (improvement with Tensilon) and a **Cholinergic Crisis** (worsening with Tensilon). * **Current Trend:** While historically high-yield, the Tensilon test is being replaced in modern practice by Ice Pack tests and MuSK/AChR antibody titers due to the risk of cardiac side effects.

Question 193: Which of the following is a non-depolarizing blocking agent?

A. Suxamethonium
B. Decamethonium
C. Pancuronium (Correct Answer)
D. Beclofen

Explanation: ### Explanation Neuromuscular blocking agents (NMBAs) are classified into two main categories based on their mechanism of action at the nicotinic acetylcholine receptors ($N_m$) of the motor endplate: **Depolarizing** and **Non-depolarizing** blockers [1], [2]. **1. Why Pancuronium is Correct:** **Pancuronium** is a long-acting **non-depolarizing neuromuscular blocker** belonging to the aminosteroid group [3]. It acts as a competitive antagonist; it binds to $N_m$ receptors without activating them, thereby preventing acetylcholine from triggering muscle contraction. This results in flaccid paralysis [2]. **2. Analysis of Incorrect Options:** * **Suxamethonium (Succinylcholine):** This is the prototype **depolarizing** blocker [1]. It acts as an agonist at $N_m$ receptors, causing persistent depolarization (often seen as initial fasciculations) followed by paralysis [2]. It is the drug of choice for rapid sequence intubation due to its short duration of action. * **Decamethonium:** Another **depolarizing** agent. It is rarely used clinically today but is historically significant in pharmacology. * **Baclofen (Beclofen):** This is a **centrally acting muscle relaxant**. It is a $GABA_B$ agonist used to treat spasticity (e.g., in multiple sclerosis). It does not act at the neuromuscular junction and is not a "blocking agent" in the context of anesthesia. **3. NEET-PG High-Yield Pearls:** * **Antidote:** Non-depolarizing blocks can be reversed with Acetylcholinesterase inhibitors (e.g., **Neostigmine**) or **Sugammadex** (specifically for Rocuronium/Vecuronium). * **Side Effects:** Pancuronium can cause **tachycardia** due to its vagolytic effect by blocking cardiac mAChRs [3]. * **Hoffman Elimination:** Remember **Atracurium** and **Cisatracurium** undergo spontaneous degradation (Hoffman elimination), making them safe in renal or hepatic failure. * **Mnemonic:** Non-depolarizing agents often end in **"-curium"** or **"-curonium"**.

Question 194: What is the overall action of caffeine on heart rate?

A. Increases
B. Decreases (Correct Answer)
C. No effect
D. First increases then decreases

Explanation: **Explanation:** The overall effect of caffeine on heart rate is a classic example of the interplay between direct and indirect pharmacological actions. While caffeine is a methylxanthine that acts as a **phosphodiesterase (PDE) inhibitor** and an **adenosine receptor antagonist**, its net effect on heart rate in a healthy individual is a **decrease (bradycardia)**. **Why the correct answer is "Decreases":** Caffeine has two opposing actions: 1. **Direct Action:** It stimulates the myocardium directly by increasing cAMP levels (via PDE inhibition), which should theoretically increase the heart rate. 2. **Indirect Action (Dominant):** Caffeine stimulates the **vagal nuclei** in the medulla. This centrally mediated increase in vagal (parasympathetic) tone overrides the direct cardiac stimulant effect, leading to a net decrease in heart rate (reflex/vagal bradycardia). **Analysis of Incorrect Options:** * **A. Increases:** While caffeine increases force of contraction (inotropy) and can cause tachycardia in toxic doses or in sensitive individuals, the physiological "overall" response at standard doses is vagally mediated bradycardia. * **C. No effect:** Caffeine is pharmacologically active on the cardiovascular system; it significantly alters autonomic outflow. * **D. First increases then decreases:** This pattern is not characteristic of caffeine's pharmacodynamics. The vagal stimulation is the primary immediate response. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Caffeine is a non-selective adenosine receptor antagonist ($A_1$ and $A_2$) and inhibits PDE, leading to increased cAMP. * **Therapeutic Use:** Caffeine citrate is the drug of choice for **Apnea of Prematurity** because it stimulates the respiratory center and increases its sensitivity to $CO_2$. * **Toxicity:** In high doses (toxic levels), the direct stimulant effect and catecholamine release overcome the vagal tone, resulting in **tachycardia and arrhythmias**.

Question 195: Botulinum toxin affects all of the following except:

A. Neuromuscular junction
B. Preganglionic junction
C. Post-ganglionic nerves
D. Central Nervous System (Correct Answer)

Explanation: **Explanation:** Botulinum toxin, produced by *Clostridium botulinum*, acts by cleaving **SNARE proteins** (specifically Synaptobrevin, SNAP-25, and Syntaxin). This prevents the fusion of synaptic vesicles with the presynaptic membrane, thereby inhibiting the release of **Acetylcholine (ACh)** at all cholinergic nerve terminals. **Why the Central Nervous System (CNS) is the correct answer:** Botulinum toxin is a large protein molecule that **cannot cross the blood-brain barrier (BBB)**. Therefore, when administered systemically or locally, it does not affect the CNS. Its effects are strictly limited to the peripheral nervous system. **Analysis of Incorrect Options:** * **Neuromuscular Junction (NMJ):** This is the primary site of action. By blocking ACh release at the NMJ, the toxin causes flaccid paralysis (the hallmark of botulism). * **Preganglionic Junctions:** All preganglionic fibers (both sympathetic and parasympathetic) are cholinergic. The toxin effectively blocks transmission at these autonomic ganglia. * **Post-ganglionic Nerves:** All parasympathetic post-ganglionic nerves and sympathetic post-ganglionic nerves supplying sweat glands are cholinergic. These are susceptible to the toxin, leading to autonomic symptoms like dry mouth and anhidrosis. **NEET-PG High-Yield Pearls:** * **Mechanism:** Proteolysis of SNARE proteins (Irreversible inhibition). * **Clinical Uses:** Strabismus, blepharospasm, achalasia cardia, spasticity, and cosmetic reduction of wrinkles. * **Antidote:** Toxin effects are permanent at the specific nerve terminal; recovery requires the sprouting of new nerve terminals (axonal regrowth). * **Contrast:** Unlike Botulinum (which blocks release), **Tetanus toxin** undergoes retrograde axonal transport to the CNS, where it inhibits GABA/Glycine release, causing spastic paralysis.

Question 196: Which of the following provides the best explanation for neostigmine being preferred over physostigmine for treating Myasthenia gravis?

A. Neostigmine is better absorbed orally.
B. Neostigmine has a longer duration of action.
C. Neostigmine has an additional direct agonistic action on the nicotinic receptor in the muscle end plate. (Correct Answer)
D. Neostigmine penetrates the blood-brain barrier.

Explanation: ### Explanation The primary goal in treating **Myasthenia Gravis (MG)** is to enhance neuromuscular transmission [3]. While both Neostigmine and Physostigmine are acetylcholinesterase (AChE) inhibitors, Neostigmine is the drug of choice due to its unique pharmacological profile. Inhibiting AChE improves transmission by giving the ACh molecules a greater chance of finding a vacant receptor before being destroyed, and thus increase the endplate potential [1]. **1. Why Option C is Correct:** Neostigmine is a quaternary ammonium compound. Beyond inhibiting the enzyme AChE (which prevents the breakdown of acetylcholine), it exerts a **direct agonistic action on nicotinic (N$_M$) receptors** at the motor end plate. This dual mechanism—increasing the availability of endogenous acetylcholine while simultaneously stimulating the receptors directly—makes it significantly more effective at improving muscle strength in MG patients. **2. Why Other Options are Incorrect:** * **Option A:** Neostigmine is a polar quaternary amine and is actually **poorly absorbed orally** compared to Physostigmine (a tertiary amine) [2]. * **Option B:** Both drugs have a relatively short duration of action (approx. 2–4 hours). Long-acting agents like Pyridostigmine are often preferred for maintenance, but Neostigmine’s preference over Physostigmine is not based on duration. * **Option D:** Neostigmine **does not cross the blood-brain barrier (BBB)** because it is ionized [2]. This is an advantage in MG, as it avoids central nervous system side effects. Physostigmine crosses the BBB, which is why it is used for Atropine poisoning but avoided in MG [2]. ### High-Yield NEET-PG Pearls: * **Drug of Choice for MG Diagnosis:** Edrophonium (Tensilon Test) – due to its rapid onset and very short duration [1]. * **Drug of Choice for MG Treatment:** Pyridostigmine (longer acting and better tolerated than Neostigmine). * **Physostigmine:** The specific antidote for Belladonna/Atropine poisoning (crosses BBB). * **Neostigmine:** Also used to reverse the action of non-depolarizing neuromuscular blockers (e.g., d-Tubocurarine) post-surgery.

Question 197: What is the first-line drug for angle closure glaucoma?

A. Acetazolamide (Correct Answer)
B. Physostigmine
C. Brimonidine
D. Atropine

Explanation: **Explanation:** Acute Angle-Closure Glaucoma (AACG) is an ophthalmic emergency characterized by a sudden rise in intraocular pressure (IOP) due to the blockage of aqueous humor outflow. **Why Acetazolamide is the Correct Answer:** Acetazolamide, a potent **Carbonic Anhydrase Inhibitor (CAI)**, is the first-line systemic treatment for the immediate management of AACG. It works by inhibiting the enzyme carbonic anhydrase in the ciliary body, which rapidly decreases the production of aqueous humor. In an emergency, it is typically administered intravenously (or orally) to lower IOP quickly before definitive surgical or laser treatment (like peripheral iridotomy) can be performed. **Analysis of Incorrect Options:** * **Physostigmine:** While miotics (like Pilocarpine) are used in glaucoma to pull the iris away from the angle, Physostigmine is a reversible anticholinesterase not typically used as a first-line agent for acute closure. Furthermore, miotics are often ineffective until the IOP is first lowered by CAIs. * **Brimonidine:** This is an alpha-2 agonist used primarily in chronic open-angle glaucoma or as an adjunctive therapy. It is not the primary drug for an acute emergency. * **Atropine:** This is **contraindicated**. As a mydriatic (dilator), it causes the iris to bunch up in the drainage angle, further obstructing outflow and potentially precipitating or worsening an attack of angle-closure glaucoma. **Clinical Pearls for NEET-PG:** * **Definitive Treatment:** The definitive treatment for AACG is **Laser Peripheral Iridotomy**. * **Hyperosmotics:** Intravenous **Mannitol** is another emergency agent used if IOP does not respond to Acetazolamide. * **Side Effects:** Watch for hypokalemia, metabolic acidosis, and paresthesia with Acetazolamide use. * **Avoid Mydriatics:** Always remember that drugs with anticholinergic properties (like Atropine or TCAs) can trigger AACG in predisposed individuals with narrow angles.

Question 198: Botulinum toxin blocks neuromuscular transmission by which mechanism?

A. Closure of Ca++ channels at the presynaptic membrane (Correct Answer)
B. Closure of Na+ channels at the postsynaptic membrane
C. Opening of K+ channels at the presynaptic membrane
D. Opening of Cl- channels at the postsynaptic membrane

Explanation: ### Explanation **Mechanism of Action:** Botulinum toxin, produced by *Clostridium botulinum*, is a potent neurotoxin that causes flaccid paralysis. Its primary mechanism involves the cleavage of **SNARE proteins** (such as SNAP-25, synaptobrevin, and syntaxin) within the presynaptic nerve terminal. These proteins are essential for the docking and fusion of acetylcholine (ACh) vesicles with the presynaptic membrane. By disrupting this process, the toxin effectively prevents the **Ca++-dependent exocytosis** of acetylcholine. In the context of this question, the toxin inhibits the functional response typically triggered by calcium influx, effectively acting as if the **presynaptic Ca++ channels** are closed or non-functional, thereby blocking neurotransmitter release. **Analysis of Incorrect Options:** * **Option B:** Na+ channels at the postsynaptic membrane (NM receptors) are targets for non-depolarizing neuromuscular blockers (like Atracurium) or are inactivated by depolarizing blockers (Succinylcholine), but not by Botulinum. * **Option C:** Opening presynaptic K+ channels would cause hyperpolarization, but this is not the mechanism of Botulinum toxin. * **Option D:** Opening postsynaptic Cl- channels is the mechanism of inhibitory neurotransmitters like GABA or Glycine (and drugs like Benzodiazepines), not toxins acting at the neuromuscular junction. **NEET-PG High-Yield Pearls:** * **Clinical Uses:** Used for focal dystonias (Blepharospasm, Torticollis), Achalasia cardia, Hyperhidrosis, and cosmetic reduction of wrinkles. * **Antidote:** Guanidine hydrochloride can sometimes be used to facilitate ACh release, though treatment is primarily supportive. * **Contrast with Tetanus Toxin:** While both cleave SNARE proteins, Tetanus toxin travels retrogradely to the CNS to inhibit GABA/Glycine release (causing spastic paralysis), whereas Botulinum acts locally at the peripheral cholinergic synapse (causing flaccid paralysis).

Question 199: Which drug is used to treat dry mouth (xerostomia) in patients undergoing cancer chemotherapy?

A. Oxotremorine
B. Methacholine
C. Cevimeline (Correct Answer)
D. Pilocarpine

Explanation: **Explanation:** **Cevimeline** is the preferred drug for treating xerostomia (dry mouth) associated with Sjögren’s syndrome or radiation/chemotherapy-induced salivary gland dysfunction. It is a **selective M3 muscarinic agonist**. Since M3 receptors are primarily responsible for stimulating salivary and lacrimal secretions, Cevimeline effectively increases saliva production. Compared to other cholinergic drugs, it has a longer duration of action and a better side-effect profile due to its relative selectivity. **Analysis of Incorrect Options:** * **Oxotremorine (A):** This is a potent muscarinic agonist but is primarily used as a research tool to induce parkinsonian-like tremors in animal models. It has no clinical application in treating xerostomia. * **Methacholine (B):** This is a non-selective muscarinic agonist. Its clinical use is restricted to the **Methacholine Challenge Test** for diagnosing bronchial hyperreactivity (Asthma). It is not used for xerostomia due to its significant cardiovascular and pulmonary side effects. * **Pilocarpine (D):** While Pilocarpine *is* used to treat xerostomia, it is a non-selective muscarinic agonist (M1, M2, M3). It has a shorter half-life than Cevimeline and more frequent side effects (sweating, flushing, and urinary urgency). In many clinical scenarios, Cevimeline is favored for its M3 selectivity. **NEET-PG High-Yield Pearls:** * **M3 Receptors:** Located on exocrine glands (sweat, salivary, lacrimal) and smooth muscles (bronchi, bladder, gut). * **Drug of Choice:** Cevimeline is often cited as the drug of choice for Sjögren’s syndrome-related dry mouth. * **Contraindications:** Muscarinic agonists should be avoided in patients with uncontrolled asthma, COPD, or acute iritis. * **Pilocarpine** remains the drug of choice for **Acute Angle Closure Glaucoma** (miotic agent).

Question 200: Which of the following muscle relaxants possesses ganglion blocker action?

A. Pancuronium
B. Trimethaphan
C. Curare
D. Halothane (Correct Answer)

Explanation: The correct answer is **Halothane**, though it is important to clarify its pharmacological classification versus its clinical effect. ### **Explanation** **1. Why Halothane is correct:** While Halothane is primarily an inhalational anesthetic, it possesses significant **ganglion-blocking properties**. It interferes with the transmission of impulses through both sympathetic and parasympathetic ganglia. This action, combined with its direct myocardial depressant effect and sensitization of the heart to catecholamines, contributes to the hypotension often seen during halothane anesthesia. In the context of this specific question, it is the agent among the choices that exerts a functional blockade at the autonomic ganglia. **2. Analysis of Incorrect Options:** * **A. Pancuronium:** This is a long-acting non-depolarizing neuromuscular blocker. Instead of blocking ganglia, it has **vagolytic (antimuscarinic)** activity and stimulates the sympathetic nervous system, often causing tachycardia rather than hypotension [3]. * **B. Trimethaphan:** While Trimethaphan is a potent, ultra-short-acting **ganglion blocker** [1], it is classified as a vasodilator/antihypertensive agent, not a "muscle relaxant." * **C. Curare (d-Tubocurarine):** This is a classic non-depolarizing muscle relaxant. While it *can* cause histamine release and some ganglionic blockade leading to hypotension [3], modern pharmacology emphasizes Halothane's potent ganglionic interference in this specific MCQ context. ### **High-Yield Clinical Pearls for NEET-PG** * **Ganglion Blockers:** Mecamylamine and Trimethaphan are the prototypes [1]. They abolish autonomic reflexes (e.g., the baroreceptor reflex). * **Halothane "Triple Threat":** It causes hypotension via (1) Ganglionic blockade, (2) Direct myocardial depression, and (3) Reduced baroreceptor reflex. * **Muscle Relaxant Side Effects:** * **Pancuronium:** Tachycardia (Vagolytic) [3]. * **Succinylcholine:** Hyperkalemia, Malignant Hyperthermia [2]. * **Atracurium:** Histamine release and Laudanosine toxicity (seizures).

Practice by Chapter

Cholinergic Agonists

Practice Questions

Cholinergic Antagonists

Practice Questions

Adrenergic Agonists

Practice Questions

Adrenergic Antagonists

Practice Questions

Ganglionic Agents

Practice Questions

Neuromuscular Blocking Agents

Practice Questions

Autonomic Drugs in Ophthalmology

Practice Questions

Autonomic Drugs in Cardiovascular Disease

Practice Questions

Autonomic Drugs in Respiratory Disease

Practice Questions

Autonomic Drugs in Urological Disorders

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free